Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Each track will spotlight a different specialty area including: oncology, cardiology, women's health and preventing burnout/supporting operational efficiency.
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.
Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.
The Covid-19 pandemic changed the way we think of the role of diagnostics not only for clinicians but also consumers. The pandemic propelled innovation of in vitro diagnostics and the at-home test kits space for chronic conditions, sexual health, and more.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.
Function Oncology goes beyond next-generation sequencing with a CRISPR-based technology that identifies targets for a patient’s cancer regardless of whether or not they are mutated. Now out of stealth, the company will present data validating its approach during the American Association for Cancer Research annual meeting.
The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Hear from healthcare executives such as Nicholas Turos, vice president of business development with Babson Diagnostics, Marcus Perez, Altera Digital Health president, and Integra Connect COO Cory Wiegert on how they are meeting the challenges of healthcare innovation.
The Covid-19 pandemic has transformed the way we think of diagnostics in our daily lives. In a recent webinar, BD Vice President for Diagnostics Nikos Pavlidis spoke with a clinician and an epidemiologist where they shared their perspectives on how testing developments have changed the way we track respiratory illnesses.
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
Lucira Health now has the first FDA authorized diagnostic that detects the novel coronavirus and influenza in a single test. But the regulatory decision comes too late for the diagnostics developer, which has filed for bankruptcy protection.
A webinar sponsored by BD scheduled for March 7 will explore how diagnostics companies are working with healthcare organizations to guard against the perfect storm of Covid-19, RSV and influenza. Register today!